Markets have often bottomed as the cannon boomed; then were already up by the time trumpets sounded.

There's a detectable fever pitch in the market now, less centered around ideas of rapid rate hikes by the Fed, but more from rumored panic over the nation's COVID policy.

'Fortune favors the brave' it is said; it's partially so in this market, where we certainly got the ignition Tuesday of the seasonal rebound we looked for and more on Wednesday.

Treacherous spinning definitely kept traders on edge Monday, during what is a normally docile few sessions ahead of Thanksgiving. Using the SPR to manipulate the market price of oil is inappropriate, it is for an emergency, there is no emergency.

Mischaracterized Inflation by economists and politicians has contributed to a rolling argument, though there's really no case to be made for 'transitory' as a word to describe this inflation. Our view of 'enduring' continues to prevail.

Rational analysis increasingly is 'missing in action' among pundits or other observers of market action, and 'risks'. Elusive goals give stocks fame more in a novelty fashion, than investment merit, though both can apply of course.

Resilience is the key word to describe this market for some time, and totally inline with our outlook for an upward-tilted Expiration last week, mild defense to start this week and then onward, potentially to another record S&P high.

A complex battle has been outlined on both sides of S&P 4400. So, having forecast the rebounds to that area, we expected no defining structure, quickly answering questions about whether there was more correction ahead.

'Raising the stakes' reasonably describes the backdrop surrounding stocks as well as longer range market prospects, fiscal conditions, geopolitical (most obvious China-Taiwan) threats, Oil prices, Debt, and even COVID's evolution.

Underperformance by many stocks, but few that are really in trouble, is reflective of rising complacency, while technicians are frustrated at the lack of breakouts or breakdowns. That's actually fine, and for this time of year really valued.

Ben Rabizadeh believes Aehr Test Systems could reach $50 by the end of 2021 and double that within two to three years.

Aehr Test Systems, today announced the pricing of its previously announced underwritten public offering of 3,846,154 shares of its common stock at a price to the public of $3.90 per share.